Restriction Factors: From Intrinsic Viral Restriction to Shaping Cellular Immunity Against HIV-1
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Antiviral restriction factors are host cellular proteins that constitute a first line of defense blocking viral replication and propagation. In addition to interfering at critical steps of the viral replication cycle, some restriction factors also act as innate sensors triggering innate responses against infections. Accumulating evidence suggests an additional role for restriction factors in promoting antiviral cellular immunity to combat viruses. Here, we review the recent progress in our understanding on how restriction factors, particularly APOBEC3G, SAMHD1, Tetherin, and TRIM5α have the cell-autonomous potential to induce cellular resistance against HIV-1 while promoting antiviral innate and adaptive immune responses. Also, we provide an overview of how these restriction factors may connect with protein degradation pathways to modulate anti-HIV-1 cellular immune responses, and we summarize the potential of restriction factors-based therapeutics. This review brings a global perspective on the influence of restrictions factors in intrinsic, innate, and also adaptive antiviral immunity opening up novel research avenues for therapeutic strategies in the fields of drug discovery, gene therapy, and vaccines to control viral infections.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
SAMHD1 is the dendritic- and myeloid-cell-specific HIV-1 restriction factor counteracted by Vpx
Laguette, N., Sobhian, B., Casartelli, N., Ringeard, M., Chable-Bessia, C., Ségéral, E., Yatim, A., Emiliani, S., Schwartz, O., & Benkirane, M. (2011) · Nature · doi:10.1038/nature10117 · Cited by 1,511 · cited 4×
“Owing to the inefficient capacity of HIV-1 to infect DCs, mainly due to the restriction exerted by SAMHD1, it has been proposed that HIV-1 might evade innate sensing (4, 77).”
BackgroundInfluentialBroad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts
Mangeat, B., Turelli, P., Caron, G., Friedli, M., Perrin, L., & Trono, D. (2003) · Nature · doi:10.1038/nature01709 · Cited by 1,486
Vpx relieves inhibition of HIV-1 infection of macrophages mediated by the SAMHD1 protein
Hrecka, K., Hao, C., Gierszewska, M., Swanson, S. K., Kesik-Brodacka, M., Srivastava, S., Florens, L., Washburn, M. P., & Skowronski, J. (2011) · Nature · doi:10.1038/nature10195 · Cited by 1,200 · cited 2×
“Some myeloid cells—monocytes, macrophages, and DCs— and CD4+ T cells ubiquitously express SAMHD1 (4, 6, 69), which regulates their cell cycle by controlling the availability of the dNTP pools.”
BackgroundAicardi–Goutières syndrome and the type I interferonopathies
Crow, Y. J., & Manel, N. (2015) · Nature Reviews Immunology · doi:10.1038/nri3850 · Cited by 925 · cited 1×
“In fact, deficiency in SAMHD1 leads to increased IFN production, upon viral DNA sensing by cGAS, and innate immune activation causing autoimmune disorders in patients (74).”
BackgroundEndogenous MHC Class II Processing of a Viral Nuclear Antigen After Autophagy
Paludan, C., Schmid, D., Landthaler, M., Vockerodt, M., Kube, D., Tuschl, T., & Münz, C. (2005) · Science · doi:10.1126/science.1104904 · Cited by 860
Lahouassa, H., Daddacha, W., Hofmann, H., Ayinde, D., Logue, E. C., Dragin, L., Bloch, N., Maudet, C., Bertrand, M., Gramberg, T., et al. (2012) · Nature Immunology · doi:10.1038/ni.2236 · Cited by 852 · cited 1×
“SAMHD1 SAMHD1 (Sterile Alpha Motif and Histidine Aspartate domaincontaining protein 1) is a deoxynucleotide triphosphohydrolase that impairs HIV-1 reverse transcription by reducing the pool of cellular dNTPs (5, 61, 62).”
BackgroundTRIM family proteins: retroviral restriction and antiviral defence
Nisole, S., Stoye, J. P., & Saïb, A. (2005) · Nature Reviews Microbiology · doi:10.1038/nrmicro1248 · Cited by 761
Sawyer, S. L., Wu, L. I., Emerman, M., & Malik, H. S. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0409853102 · Cited by 688
Cyclophilin A retrotransposition into TRIM5 explains owl monkey resistance to HIV-1
Sayah, D. M., Sokolskaja, E., Berthoux, L., & Luban, J. (2004) · Nature · doi:10.1038/nature02777 · Cited by 662 · cited 3×
“The exception is found in New World owl monkeys where the PRYSPRY domain of TRIM5α has been replaced by a cyclophilin A binding domain (TRIMCypA) that hampers HIV-1 infection very vigorously (113, 119, 126, 127).”
BackgroundTRIM5 is an innate immune sensor for the retrovirus capsid lattice
Pertel, T., Hausmann, S., Morger, D., Züger, S., Guerra, J., Lascano, J., Reinhard, C., Santoni, F. A., Uchil, P. D., Chatel, L., et al. (2011) · Nature · doi:10.1038/nature09976 · Cited by 645 · cited 2×
“On the other hand, TRIM5α, TRIM21, and TRIM25 poly-ubiquitination activities have been recently shown to bridge viral degradation with the activation of innate immunity (149, 175, 176).”
Background
Cited by
Gene therapy using haematopoietic stem and progenitor cells
Ferrari, G., Thrasher, A. J., & Aiuti, A. (2021) · Nature Reviews Genetics · doi:10.1038/s41576-020-00298-5 · Cited by 254
Therapeutic Role of Inflammasome Inhibitors in Neurodegenerative Disorders
Lahooti, B., Chhibber, T., Bagchi, S., Varahachalam, S. P., & Jayant, R. D. (2021) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2020.11.004 · Cited by 50
Development of Lentiviral Vectors for HIV-1 Gene Therapy with Vif-Resistant APOBEC3G
Delviks-Frankenberry, K. A., Ackerman, D., Timberlake, N. D., Hamscher, M., Nikolaitchik, O. A., Hu, W.-S., Torbett, B. E., & Pathak, V. K. (2019) · Molecular Therapy Nucleic Acids · doi:10.1016/j.omtn.2019.10.024 · Cited by 21
Metadata
- Authors
- Colomer-Lluch, M., Ruiz, A., Moris, A., & Prado, J. G.
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2018-12-06
- Volume
- 9
- Pages
- 2876-2876
- ISSN
- 1664-3224 (ISSN-L)
- OpenAlex
- W2904925953
- Cited by
- 167
- References
- 13
- FWCI
- 9.10
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.